celecoxib has been researched along with Cancer of Cervix in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Serum levels of squamous cell carcinoma antigen and the proliferative potential and subsets of peripheral T cells before and after celecoxib treatment were also analyzed." | 2.71 | Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. ( Battaglia, A; Ferrandina, G; Gessi, M; Lauriola, L; Legge, F; Navarra, P; Ranelletti, FO; Salutari, V; Scambia, G; Testa, AC; Tringali, G; Werner, U, 2003) |
| "hTERT was depleted in gastric and cervical cancer cells using small interfering RNA (siRNA) and analysed for COX2 expression using quantitative PCR and immunoblotting." | 1.39 | Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects. ( Björkholm, M; Jia, J; Li, B; Liang, X; Liu, T; Xu, D, 2013) |
| "Cervical cancer is one of the most common cancers worldwide." | 1.38 | Do NSAIDs inhibit growth of precancerous cervical cells in vitro? ( Charoenvilaisiri, S; Poomkokruk, A; Sakonlaya, D; Tapanadechopone, P, 2012) |
| "Celecoxib pretreatment radiosensitizes HeLa cells via a mechanism dependent on down-regulation of COX-2 and VEGF-C." | 1.38 | Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression. ( Liu, H; Mi, JQ; Tian, XY; Wang, AH; Wang, RF; Yu, JJ, 2012) |
| "Celecoxib treatment induced Bak expression, whereas cell treated with siGADD153 or TPCK showed lower levels of celecoxib-induced Bak up-regulation." | 1.34 | GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. ( Hwang, CI; Juhnn, YS; Kim, SH; Lee, JH; Park, WY; Song, YS, 2007) |
| "Celecoxib treatment induced Bak expression, whereas cell transfected with siGADD153 showed lower levels of celecoxib-induced Bak upregulation." | 1.33 | GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. ( Hwang, CI; Kim, SH; Lee, JH; Park, WY; Song, YS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, M | 1 |
| Yang, H | 1 |
| Wu, K | 1 |
| Ji, Y | 1 |
| Ju, L | 1 |
| Lu, X | 1 |
| Grabosch, SM | 2 |
| Shariff, OM | 2 |
| Helm, CW | 2 |
| Yoysungnoen, B | 1 |
| Bhattarakosol, O | 1 |
| Changtam, C | 1 |
| Patumraj, S | 1 |
| Liu, T | 1 |
| Liang, X | 1 |
| Li, B | 1 |
| Björkholm, M | 1 |
| Jia, J | 1 |
| Xu, D | 1 |
| Sakonlaya, D | 1 |
| Tapanadechopone, P | 1 |
| Poomkokruk, A | 1 |
| Charoenvilaisiri, S | 1 |
| Kim, JE | 1 |
| Lee, JI | 1 |
| Jin, DH | 1 |
| Lee, WJ | 1 |
| Park, GB | 1 |
| Kim, S | 1 |
| Kim, YS | 1 |
| Wu, TC | 1 |
| Hur, DY | 1 |
| Kim, D | 1 |
| Wulff, JL | 1 |
| Setiawati, A | 2 |
| Rader, JS | 1 |
| Sill, MW | 1 |
| Beumer, JH | 1 |
| Lankes, HA | 1 |
| Benbrook, DM | 1 |
| Garcia, F | 1 |
| Trimble, C | 1 |
| Tate Thigpen, J | 1 |
| Lieberman, R | 1 |
| Zuna, RE | 1 |
| Leath, CA | 1 |
| Spirtos, NM | 1 |
| Byron, J | 1 |
| Thaker, PH | 1 |
| Lele, S | 1 |
| Alberts, D | 1 |
| Weidhaas, JB | 2 |
| Li, SX | 1 |
| Winter, K | 5 |
| Ryu, J | 4 |
| Jhingran, A | 2 |
| Miller, B | 3 |
| Dicker, AP | 4 |
| Gaffney, D | 1 |
| Saha, B | 1 |
| Adhikary, A | 1 |
| Ray, P | 1 |
| Saha, S | 1 |
| Chakraborty, S | 1 |
| Mohanty, S | 1 |
| Das, K | 1 |
| Mukherjee, S | 1 |
| Mazumdar, M | 1 |
| Lahiri, L | 1 |
| Hossain, DM | 1 |
| Sa, G | 1 |
| Das, T | 1 |
| Deckmann, K | 1 |
| Rörsch, F | 1 |
| Geisslinger, G | 1 |
| Grösch, S | 1 |
| Wang, AH | 1 |
| Tian, XY | 1 |
| Yu, JJ | 1 |
| Mi, JQ | 1 |
| Liu, H | 1 |
| Wang, RF | 1 |
| Doll, CM | 1 |
| Gaffney, DK | 4 |
| Ryu, JK | 1 |
| Miller, BE | 1 |
| Magliocco, AM | 1 |
| Ferrandina, G | 2 |
| Ranelletti, FO | 2 |
| Legge, F | 2 |
| Lauriola, L | 1 |
| Salutari, V | 2 |
| Gessi, M | 1 |
| Testa, AC | 1 |
| Werner, U | 1 |
| Navarra, P | 1 |
| Tringali, G | 1 |
| Battaglia, A | 1 |
| Scambia, G | 2 |
| Kammerer, S | 1 |
| Kim, SH | 3 |
| Song, SH | 1 |
| Kim, SG | 1 |
| Chun, KS | 1 |
| Lim, SY | 1 |
| Na, HK | 1 |
| Kim, JW | 1 |
| Surh, YJ | 1 |
| Bang, YJ | 1 |
| Song, YS | 3 |
| Fuhrman, C | 1 |
| Flinner, R | 1 |
| Greven, K | 3 |
| Forbes, A | 1 |
| Kerlin, K | 1 |
| Nichols, RC | 1 |
| Zempolich, K | 1 |
| Hwang, CI | 2 |
| Park, WY | 2 |
| Lee, JH | 2 |
| Martinelli, E | 1 |
| Fattorossi, A | 1 |
| Lorusso, D | 1 |
| Zannoni, G | 1 |
| Vellone, V | 1 |
| Paglia, A | 1 |
| Herrera, FG | 1 |
| Chan, P | 1 |
| Doll, C | 1 |
| Milosevic, M | 1 |
| Oza, A | 1 |
| Syed, A | 1 |
| Pintilie, M | 1 |
| Levin, W | 1 |
| Manchul, L | 1 |
| Fyles, A | 1 |
| Eifel, PJ | 2 |
| Avizonis, V | 2 |
| Fromm, M | 2 |
| Juhnn, YS | 1 |
| Small, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)[NCT00081263] | Phase 2 | 130 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Whether or not patients with CIN 2/3 or CIN 3 upon entry experience a complete remission (or partial regression to CIN 1) in the post-treatment excisional biopsy. (NCT00081263)
Timeframe: Post treatment evaluation was done 14 to 18 weeks after treatment randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Celecoxib) | 40 |
| Arm II (Placebo) | 34.1 |
Number of participants with a grade of 3 or higher during the treatment period. (NCT00081263)
Timeframe: Assessed every cycle while on treatment, 30 days after the last cycle of treatment
| Intervention | participants (Number) | |
|---|---|---|
| Gastrointestinal | Pain | |
| Arm I (Celecoxib) | 1 | 0 |
| Arm II (Placebo) | 0 | 1 |
2 reviews available for celecoxib and Cancer of Cervix
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 In | 2018 |
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitor | 2014 |
7 trials available for celecoxib and Cancer of Cervix
| Article | Year |
|---|---|
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adolescent; Adult; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Doub | 2017 |
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens, Neoplasm; Apoptosis; Blood Vessels; Carcinoma, Sq | 2003 |
Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Celecoxib; Cisplatin; Combined Modali | 2005 |
Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cytokines; Endostatins; Enzyme-Linked Immunosorbent Assay | 2006 |
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cell Hypoxia; Combined Modality Therapy; Cyclooxygenase 2 | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
15 other studies available for celecoxib and Cancer of Cervix
| Article | Year |
|---|---|
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
Topics: Binding Sites; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug De | 2014 |
Combinational Treatment Effect of Tetrahydrocurcumin and Celecoxib on Cervical Cancer Cell-Induced Tumor Growth and Tumor Angiogenesis in Nude Mice.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Celecoxib; Combined Modality Therapy; Curcumin; Cycloox | 2016 |
Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Female; Gene Knoc | 2013 |
Do NSAIDs inhibit growth of precancerous cervical cells in vitro?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Line; C | 2012 |
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic A | 2014 |
Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells.
Topics: Apoptosis; Blotting, Western; Celecoxib; Cell Cycle Checkpoints; Cell Division; Cell Proliferation; | 2016 |
Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.
Topics: Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; Cyclooxygenase Inhibitors; F | 2009 |
Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Base Sequence; Celecoxib; Cell Cycle Proteins; Ce | 2012 |
Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1.
Topics: Celecoxib; Dinoprostone; Early Growth Response Protein 1; Electrophoretic Mobility Shift Assay; Fema | 2012 |
Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression.
Topics: Celecoxib; Cell Proliferation; Cyclooxygenase 2; Female; HeLa Cells; Humans; Immunohistochemistry; P | 2012 |
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinica | 2013 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; | 2004 |
GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Femal | 2006 |
GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, Western; Celecoxib; Cyclooxygenase | 2007 |